Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
This combination is commonly prescribed when diet, exercise, and single-drug therapy are not sufficient to maintain optimal glycemic control
59 Whether ROS derived from the Nox activation has a causal role in the development of hypertension was investigated by several animal studies using specific knockdown of Nox subunits
Therefore, glucose administration is commonly a component of managing patients with urea cycle disorders
doi: 10.3390/antiox11112133
[1] Fielding, Roger et al